Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: an Open-label Randomized Clinical Trial

Next Previous
X
Search
Trial Profile

DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: an Open-label Randomized Clinical Trial

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir/lamivudine (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms PASO-DOBLE

    • Most Recent Events

    • 23 Jul 2024 Primary endpoint has been met (Proportion of patients with plasma HIV-1 RNA 50 copies/mL) , according to a ViiV Healthcare media release.
    • 23 Jul 2024 According to a ViiV Healthcare media release, announced 48-week findings from PASO DOBLE trial, for treatment of HIV-1 in people who are virologically suppressed and who could benefit from treatment optimisation.
    • 15 Jul 2024 According to a ViiV Healthcare media release, results form this study will be presented at the 25th International AIDS Conference in Munich, Germany (22 -26 July).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top